During hepatitis C virus (HCV) infection, liver fibrosis progression after renal transplantation remains controversial.
In this study, published in the November issue of Gastroenterology, a research team assessed liver histopathologic features during HCV infection, between renal transplant recipients (group 1, n = 30).
They compared these with matched groups of hemodialyzed patients (group 2, n = 30), and controls without renal disease and untreated for HCV (group 3, n = 30).
Patients in group 1 were matched at first liver biopsy (LB) using the main factors known to influence progression of fibrosis.
Group 1 patients were also matched with those in group 3 between 2 consecutive LBs, performed 37 months apart.
|Liver fibrosis progression low in renal transplant recipients with HCV.|
The team evaluated the LBs according to the Knodell index, METAVIR score, and rate of fibrosis progression per year (fibrosis unit).
The researchers found that the rate of fibrosis progression per year between the first and second LB was significantly lower in group 1 than group 3.
At the second LB, the Knodell index and activity or fibrosis in METAVIR were lower in group 1 than group 3.
Dr Laurent Alric's team concluded, "Our study suggests that liver fibrosis progression is low in most HCV-infected renal transplant recipients with moderate liver disease at baseline".